Barclays Upgrades IQVIA Amid AI Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy IQV?
Source: seekingalpha
IQVIA Holdings Inc's stock fell 5% and hit a 5-day low amid broader market declines, with the Nasdaq-100 down 1.64% and the S&P 500 down 1.41%.
Barclays upgraded IQVIA from Equal-weight to Overweight, asserting that concerns over AI's impact on contract research organizations (CROs) are overstated, presenting attractive entry points for investors. Analysts believe the recent sell-off has reset valuations to appealing levels, making IQVIA a strong candidate for both short-term and long-term investment.
The upgrade from Barclays suggests a potential rebound for IQVIA as the market adjusts to the perceived risks associated with AI, indicating that the stock may offer good value for investors looking to enter at this time.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IQV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IQV
Wall Street analysts forecast IQV stock price to rise
15 Analyst Rating
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 166.160
Low
215.00
Averages
258.31
High
290.00
Current: 166.160
Low
215.00
Averages
258.31
High
290.00
About IQV
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IQVIA Launches AI Platform IQVIA.ai to Transform Life Sciences Operations
- Platform Launch: IQVIA announced the launch of IQVIA.ai at NVIDIA GTC, a unified agentic AI platform designed to help life sciences organizations transform operations, enhance decision-making, and drive innovation across clinical, commercial, and real-world domains.
- Deepened Technical Collaboration: The collaboration with NVIDIA, ongoing for over a year, has led to the development of an AI infrastructure that allows IQVIA.ai to securely learn from complex operational feedback while adhering to healthcare regulatory and privacy standards, promoting responsible AI adoption at scale.
- Increased Industry Trust: Currently, 19 of the top 20 pharmaceutical companies have begun integrating IQVIA agents into their workflows, underscoring broad industry trust in IQVIA's AI capabilities and further solidifying its market position.
- Focus on High-Value Use Cases: The initial release of IQVIA.ai will concentrate on high-value use cases across clinical, commercial, and real-world applications, with additional agents and capabilities expected to launch in Q4 to meet the growing market demand.
See More
Barclays Upgrades IQVIA and Medpace Ratings Amid AI Concerns
- Rating Upgrade: Barclays upgraded IQVIA (IQV) and Medpace (MEDP) from Equal-weight to Overweight, asserting that concerns over AI's impact on contract research organizations (CROs) are overstated, thus presenting attractive entry points for both short-term and long-term investors.
- Stock Performance: Over the past 12 months, Medpace's stock has plummeted by over 46%, while IQVIA has seen a decline of more than 5%, with analysts believing that the sell-off has reset valuations to appealing levels suitable for investor entry.
- Competitor Downgrades: Barclays downgraded Avantor (AVTR) and Pacific Biosciences (PACB) to Underweight, indicating limited upside potential for these companies and suggesting that it may take time for them to catch up as their turnaround stories unfold gradually.
- Market Outlook: While AI is perceived to have a greater impact on CROs, analysts believe fears regarding AI disruption are exaggerated, and both IQVIA and Medpace stocks remain attractive, especially as Medpace's valuation has meaningfully returned to normal levels.
See More
Prescription Medication Costs Can Be Overwhelming: Tips for Finding the Best Prices.
Challenges in Drug Coverage: Navigating drug coverage in the current retirement system is complex and requires significant effort and understanding from individuals.
Increasing Difficulty: The process of managing drug coverage is becoming increasingly challenging, highlighting the need for better resources and support for retirees.
See More
IQVIA Executive to Speak at Barclays Healthcare Conference
- Executive Speaking Engagement: IQVIA's CFO Mike Fedock is scheduled to speak at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026, at 9:30 AM ET, highlighting the company's leadership in the healthcare sector.
- Live Webcast Availability: The presentation will be available via live audio webcast on the IQVIA Investor Relations website, with a replay accessible later that day, ensuring timely access to key information for investors and stakeholders.
- Company Background Overview: IQVIA is a leading global provider of clinical research services with approximately 93,000 employees, dedicated to accelerating the development and commercialization of innovative medical treatments through high-quality health data and advanced analytics.
- Privacy Protection Commitment: IQVIA is at the forefront of protecting patient privacy, utilizing a variety of privacy-enhancing technologies to ensure compliance with stringent privacy and safety standards while analyzing health data.
See More
IQVIA Releases 2025 Sustainability Report Highlighting Key Innovations
- Employee Investment: In 2025, IQVIA expanded AI and data analytics training, generating over 230,000 employee engagements and involving more than 2,000 in leadership development programs, thereby enhancing its global leadership pipeline and exceeding Fortune 500 engagement benchmarks.
- AI and Technology Innovation: IQVIA advanced its AI strategy by expanding key partnerships and launching new AI solutions, ensuring compliance in privacy and patient safety, which further solidifies its technological leadership in the healthcare sector.
- Healthcare Accessibility: In 2025, IQVIA activated clinical trial sites in Brazil and Argentina, enrolling 5,700 participants towards a global target of 47,000, ensuring representation of underserved patient populations in cardiovascular research.
- Environmental Impact: IQVIA achieved 100% My Green Lab certification for its global laboratory network, redesigned clinical trial test kits to use at least 98% recycled materials, and reduced packaging emissions in cold chain logistics by 70%, demonstrating its commitment to sustainable research.
See More
IQVIA Releases 2025 Sustainability Report Highlighting Progress
- Sustainability Progress: IQVIA's 2025 Sustainability Report highlights advancements across its People, Public, and Planet pillars, demonstrating the company's commitment to accelerating innovation for a healthier world.
- Global Workforce: With approximately 93,000 employees across over 100 countries, IQVIA enhances its capabilities in medical innovation and commercialization, leveraging expertise in healthcare, life sciences, and data science.
- Privacy Protection Technologies: The company employs a variety of privacy-enhancing technologies to safeguard individual privacy while generating and analyzing data, enabling healthcare stakeholders to identify disease patterns and optimize treatment pathways.
- Commitment to Responsible AI Use: IQVIA is dedicated to using AI responsibly, ensuring its AI capabilities meet high standards of privacy, compliance, and patient safety, thereby enhancing industry trust and service precision.
See More
IQVIA Launches AI Platform IQVIA.ai to Transform Life Sciences Operations
- Platform Launch: IQVIA announced the launch of IQVIA.ai at NVIDIA GTC, a unified agentic AI platform designed to help life sciences organizations transform operations, enhance decision-making, and drive innovation across clinical, commercial, and real-world domains.
- Deepened Technical Collaboration: The collaboration with NVIDIA, ongoing for over a year, has led to the development of an AI infrastructure that allows IQVIA.ai to securely learn from complex operational feedback while adhering to healthcare regulatory and privacy standards, promoting responsible AI adoption at scale.
- Increased Industry Trust: Currently, 19 of the top 20 pharmaceutical companies have begun integrating IQVIA agents into their workflows, underscoring broad industry trust in IQVIA's AI capabilities and further solidifying its market position.
- Focus on High-Value Use Cases: The initial release of IQVIA.ai will concentrate on high-value use cases across clinical, commercial, and real-world applications, with additional agents and capabilities expected to launch in Q4 to meet the growing market demand.
See More
Barclays Upgrades IQVIA and Medpace Ratings Amid AI Concerns
- Rating Upgrade: Barclays upgraded IQVIA (IQV) and Medpace (MEDP) from Equal-weight to Overweight, asserting that concerns over AI's impact on contract research organizations (CROs) are overstated, thus presenting attractive entry points for both short-term and long-term investors.
- Stock Performance: Over the past 12 months, Medpace's stock has plummeted by over 46%, while IQVIA has seen a decline of more than 5%, with analysts believing that the sell-off has reset valuations to appealing levels suitable for investor entry.
- Competitor Downgrades: Barclays downgraded Avantor (AVTR) and Pacific Biosciences (PACB) to Underweight, indicating limited upside potential for these companies and suggesting that it may take time for them to catch up as their turnaround stories unfold gradually.
- Market Outlook: While AI is perceived to have a greater impact on CROs, analysts believe fears regarding AI disruption are exaggerated, and both IQVIA and Medpace stocks remain attractive, especially as Medpace's valuation has meaningfully returned to normal levels.
See More
Prescription Medication Costs Can Be Overwhelming: Tips for Finding the Best Prices.
Challenges in Drug Coverage: Navigating drug coverage in the current retirement system is complex and requires significant effort and understanding from individuals.
Increasing Difficulty: The process of managing drug coverage is becoming increasingly challenging, highlighting the need for better resources and support for retirees.
See More
IQVIA Executive to Speak at Barclays Healthcare Conference
- Executive Speaking Engagement: IQVIA's CFO Mike Fedock is scheduled to speak at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026, at 9:30 AM ET, highlighting the company's leadership in the healthcare sector.
- Live Webcast Availability: The presentation will be available via live audio webcast on the IQVIA Investor Relations website, with a replay accessible later that day, ensuring timely access to key information for investors and stakeholders.
- Company Background Overview: IQVIA is a leading global provider of clinical research services with approximately 93,000 employees, dedicated to accelerating the development and commercialization of innovative medical treatments through high-quality health data and advanced analytics.
- Privacy Protection Commitment: IQVIA is at the forefront of protecting patient privacy, utilizing a variety of privacy-enhancing technologies to ensure compliance with stringent privacy and safety standards while analyzing health data.
See More
IQVIA Releases 2025 Sustainability Report Highlighting Key Innovations
- Employee Investment: In 2025, IQVIA expanded AI and data analytics training, generating over 230,000 employee engagements and involving more than 2,000 in leadership development programs, thereby enhancing its global leadership pipeline and exceeding Fortune 500 engagement benchmarks.
- AI and Technology Innovation: IQVIA advanced its AI strategy by expanding key partnerships and launching new AI solutions, ensuring compliance in privacy and patient safety, which further solidifies its technological leadership in the healthcare sector.
- Healthcare Accessibility: In 2025, IQVIA activated clinical trial sites in Brazil and Argentina, enrolling 5,700 participants towards a global target of 47,000, ensuring representation of underserved patient populations in cardiovascular research.
- Environmental Impact: IQVIA achieved 100% My Green Lab certification for its global laboratory network, redesigned clinical trial test kits to use at least 98% recycled materials, and reduced packaging emissions in cold chain logistics by 70%, demonstrating its commitment to sustainable research.
See More
IQVIA Releases 2025 Sustainability Report Highlighting Progress
- Sustainability Progress: IQVIA's 2025 Sustainability Report highlights advancements across its People, Public, and Planet pillars, demonstrating the company's commitment to accelerating innovation for a healthier world.
- Global Workforce: With approximately 93,000 employees across over 100 countries, IQVIA enhances its capabilities in medical innovation and commercialization, leveraging expertise in healthcare, life sciences, and data science.
- Privacy Protection Technologies: The company employs a variety of privacy-enhancing technologies to safeguard individual privacy while generating and analyzing data, enabling healthcare stakeholders to identify disease patterns and optimize treatment pathways.
- Commitment to Responsible AI Use: IQVIA is dedicated to using AI responsibly, ensuring its AI capabilities meet high standards of privacy, compliance, and patient safety, thereby enhancing industry trust and service precision.
See More
